Anti-TNFα Biotherapeutics Currently Licensed for the Treatment of RA
infliximab (Remicade® ) | adalimumab (Humira™) | etanercept (Enbrel® ) | |
---|---|---|---|
Structure | Chimeric monoclonal Antibody | Recombinant human monoclonal antibody | p75 TNF receptor/ Fc fusion protein |
Specificity | Soluble (trimer andmonomer) TNFα , transmembrane TNFα receptor-bound TNFα | Soluble TNFα and transmembrane TNFα , and | Soluble and transmembrane TNFα and lymphotoxin |
Cell lysis | Yes | Yes | No |
Maintenance dosing | 3 mg/kg every 8 weeks via intravenous infusion | 40 mg every 2 weeks subcutaneously | 25 mg twice weekly subcutaneously |
Serum half-life | 8–10 days | 14–19 days | 4.8 days |
Immune 8.5% response inRA patients | 5% | 5% |